 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
71 News |  |
| «12 |
- || citarinostat (ACY-241) / BMS
Trial completion date, Trial primary completion date, Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - May 1, 2018
P1a/1b, N=81, Active, not recruiting, Sponsor: Celgene
Trial completion date: Jun 2018 --> Jul 2019 | Trial primary completion date: Feb 2018 --> Jan 2019
- | Review, Journal: Deacetylase Inhibitors as a Novel Modality in the Treatment of Multiple Myeloma. (Pubmed Central) - Dec 30, 2017
Panobinostat, a pan-DACi, has shown significant clinical benefit and is the first DACi approved for the treatment of MM...Ricolinostat and ACY-241, which selectively inhibit HDAC6 and the aggresome pathway, are currently being studied in combination with dexamethasone and bortezomib or an immunomodulatory drug for the treatment of relapsed and refractory MM. In this review, we discuss the data from key clinical trials investigating deacetylase inhibitors as novel treatment options for MM.
- citarinostat (ACY-241) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (clinicaltrials.gov) - Nov 6, 2017
P1b, N=41, Recruiting, Sponsor: Celgene
In this review, we discuss the data from key clinical trials investigating deacetylase inhibitors as novel treatment options for MM. Trial primary completion date: Dec 2017 --> Oct 2018
- citarinostat (ACY-241) / BMS, PVX-410 / OncoPep
Enrollment closed, Epigenetic controller: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov) - Oct 31, 2017
P1b, N=26, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2017 --> Oct 2018 Recruiting --> Active, not recruiting
- citarinostat (ACY-241) / BMS
Trial primary completion date, Combination therapy, Metastases: ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 2, 2017
P1b, N=41, Recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Mar 2018
- citarinostat (ACY-241) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab (clinicaltrials.gov) - Aug 24, 2017
P1b, N=1, Completed, Sponsor: Celgene
Trial primary completion date: Nov 2017 --> Mar 2018 Recruiting --> Completed | N=36 --> 1 | Initiation date: May 2016 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Apr 2017
- || citarinostat (ACY-241) / BMS
Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Jun 14, 2017
P1a/1b, N=78, Active, not recruiting, Sponsor: Celgene
Recruiting --> Completed | N=36 --> 1 | Initiation date: May 2016 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Apr 2017 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1a/1b | N=115 --> 78 | Trial primary completion date: Apr 2017 --> Mar 2018
- citarinostat (ACY-241) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (clinicaltrials.gov) - Jun 14, 2017
P1b, N=41, Recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1a/1b | N=115 --> 78 | Trial primary completion date: Apr 2017 --> Mar 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- citarinostat (ACY-241) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Phase classification, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (clinicaltrials.gov) - Apr 6, 2017
P1b, N=41, Recruiting, Sponsor: Celgene
Trial primary completion date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Phase classification: P1 --> P1b | Initiation date: Jan 2016 --> Sep 2016 | Trial primary completion date: Jan 2017 --> Sep 2017
- citarinostat (ACY-241) / BMS, PVX-410 / OncoPep
Enrollment open, Epigenetic controller: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov) - Jan 19, 2017
P1b, N=26, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Phase classification: P1 --> P1b | Initiation date: Jan 2016 --> Sep 2016 | Trial primary completion date: Jan 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- citarinostat (ACY-241) / BMS
Phase classification, Trial primary completion date, Combination therapy, Metastases: ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 14, 2016
P1b, N=41, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Phase classification: P1 --> P1b | Trial primary completion date: Dec 2016 --> Oct 2017
- || citarinostat (ACY-241) / BMS
Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Oct 13, 2016
P1, N=115, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Phase classification: P1 --> P1b | Trial primary completion date: Dec 2016 --> Oct 2017 Trial primary completion date: Jan 2017 --> Apr 2017
- | citarinostat (ACY-241) / BMS, PVX-410 / OncoPep
New P1 trial, Epigenetic controller: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov) - Sep 1, 2016
P1b, N=26, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || citarinostat (ACY-241) / BMS
Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2016
P1, N=115, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Trial primary completion date: Jan 2017 --> Apr 2017 N=68 --> 115
- citarinostat (ACY-241) / BMS
Enrollment open, Combination therapy, Metastases: ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2016
P1, N=41, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
N=68 --> 115 Not yet recruiting --> Recruiting
- | citarinostat (ACY-241) / BMS, Opdivo (nivolumab) / BMS
New P1 trial, Combination therapy, PD(L)-1 Biomarker: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (clinicaltrials.gov) - Dec 18, 2015
P1, N=41, Not yet recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
- | citarinostat (ACY-241) / BMS
New P1 trial, Combination therapy, Metastases: ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 16, 2015
P1, N=41, Not yet recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
- ||| citarinostat (ACY-241) / BMS
Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Apr 29, 2015
P1, N=68, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| citarinostat (ACY-241) / BMS
Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Mar 27, 2015
P1, N=68, Not yet recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated